[Prevention and treatment of anemia during endoprosthetic replacement of large joints].
Endoprosthetic replacement of large joints is frequently followed by great blood loss and evolving postoperative anemia. Three hundred and thirty-seven cases of endoprosthetic hip joint replacement were retrospectively analyzed. The total frequency of allogenic hemotransfusion was 16.9%. The data of the analysis made and the review of literature support that preoperative anemia and revising intervention are the leading risk factors of allogenic hemotransfusion. Allogenic packed red blood cell transfusion is associated with the higher frequency of postoperative complications and longer hospitalization. The routine use of intraoperative autohemotransfusion has shown its low efficiency while drainage blood reinfusion can reduce the need for donor blood preparations. At present there is a great variety of effective agents whose introduction into clinical practice makes it possible to considerably reduce the need for allogenic hemotransfusion during endoprosthetic replacement of large joints and to improve the results of treatment.
D B
DB
Borisov
S V
SV
Iudin
A A
AA
Tiuriapin
A A
AA
Kapinos
I V
IV
Vyl'iurov
E V
EV
Kazakevich
D000740:Anemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D001782:Blood Donors; D016063:Blood Loss, Surgical; D001803:Blood Transfusion; D001804:Blood Transfusion, Autologous; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
D006454:Hemoglobins